CMS Open Payments · Program Year 2024
Dimension Inx Corp
Dimension Inx Corp reported $1,188.67 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 2 transactions.
- $1.2K
- All-tracks total
- 2
- Transactions
- 2
- Recipients
- #1834
- of 1,925 companies
Dimension Inx Corp reported $1,188.67 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1834 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,188.67, averaging $594.34 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dimension-inx-corp Dimension Inx Corp
$1.2K · #1834/1,925 · 0.0% industry · PY2024
- TOT $1.2K
- RANK #1834
- SHARE 0.0%
- TXN 2
- RCP 2
- CAT 2
- GEN $1.2K
- TOP1 84.1%
- PY 2024
Volume peers
Nearest volume peer: Lazarus 3D ($1.2K)
Dimension Inx Corp sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Dimension Inx Corp
Averaging $594.34 per transaction and $594.34 per recipient, Dimension Inx Corp's Program Year 2024 total comes to $1,188.67 across 2 transactions and 2 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1834 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Consulting Fee" leads the 2-category general-payment breakdown below at $1.0K (84.1% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 2 types of general payments, Dimension Inx Corp's largest category was "Consulting Fee" at $1.0K - 84.1% of General Payments.
How Dimension Inx Corp divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.0K | 1 | 84.1% |
| Food and Beverage | $188.67 | 1 | 15.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,188.67 (100.0%) of $1,188.67 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dimension Inx Corp
The five named recipients with the highest reported General Payments from this company
- 1
Derek Steinbacher
$1,000.00 across 1 reported transactions
- 2
Daniel Oreadi
$188.67 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dimension Inx Corp's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dimension Inx Corp.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dimension Inx Corp.
Showing 6 of 1,924 companies with CMS-reported payment data.
GastroKlenz, Inc. DBA CloudCath
Nsk America Corporation
Labcorp Holdings Inc.
Advanced Critical Devices, Inc.
Dash Medical Gloves LLC
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.